Ovarian cancer is the fifth most common cause of cancer death in women in the United States. The majority of patients with ovarian cancer experience disease recurrence and receive second-line and sometimes several lines of therapy. Recurrent ovarian cancer is often resistant to chemotherapy, thus limiting the treatment options. Advances in technology and medical research have identified VEGF and PARP as targets for therapy, leading to the development of antiangiogenesis agents and PARP inhibitors. This activity will examine novel targeted therapy for recurrent advanced ovarian cancer.